BIOMAT Database Logo BIOMAT Database Logo

Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. 1999

R W Herzog, and E Y Yang, and L B Couto, and J N Hagstrom, and D Elwell, and P A Fields, and M Burton, and D A Bellinger, and M S Read, and K M Brinkhous, and G M Podsakoff, and T C Nichols, and G J Kurtzman, and K A High
Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, 19104, USA.

Hemophilia B is a severe X-linked bleeding diathesis caused by the absence of functional blood coagulation factor IX, and is an excellent candidate for treatment of a genetic disease by gene therapy. Using an adeno-associated viral vector, we demonstrate sustained expression (>17 months) of factor IX in a large-animal model at levels that would have a therapeutic effect in humans (up to 70 ng/ml, adequate to achieve phenotypic correction, in an animal injected with 8.5x10(12) vector particles/kg). The five hemophilia B dogs treated showed stable, vector dose-dependent partial correction of the whole blood clotting time and, at higher doses, of the activated partial thromboplastin time. In contrast to other viral gene delivery systems, this minimally invasive procedure, consisting of a series of percutaneous intramuscular injections at a single timepoint, was not associated with local or systemic toxicity. Efficient gene transfer to muscle was shown by immunofluorescence staining and DNA analysis of biopsied tissue. Immune responses against factor IX were either absent or transient. These data provide strong support for the feasibility of the approach for therapy of human subjects.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008297 Male Males
D002836 Hemophilia B A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008) Christmas Disease,Factor IX Deficiency,Deficiency, Factor IX,F9 Deficiency,Haemophilia B,Hemophilia B Leyden,Hemophilia B(M),Plasma Thromboplastin Component Deficiency,Bs, Hemophilia,Deficiencies, F9,Deficiencies, Factor IX,Deficiency, F9,Disease, Christmas,F9 Deficiencies,Factor IX Deficiencies,Haemophilia Bs,Hemophilia Bs,Hemophilia Bs (M)
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005164 Factor IX Storage-stable blood coagulation factor acting in the intrinsic pathway of blood coagulation. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease). Autoprothrombin II,Christmas Factor,Coagulation Factor IX,Plasma Thromboplastin Component,Blood Coagulation Factor IX,Factor 9,Factor IX Complex,Factor IX Fraction,Factor Nine,Factor IX, Coagulation
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000229 Dependovirus A genus of the family PARVOVIRIDAE, subfamily PARVOVIRINAE, which are dependent on a coinfection with helper adenoviruses or herpesviruses for their efficient replication. The type species is Adeno-associated virus 2. Adeno-Associated Viruses,Dependoparvovirus,Adeno-Associated Virus,Virus, Adeno-Associated,Viruses, Adeno-Associated,Adeno Associated Virus,Adeno Associated Viruses,Dependoparvoviruses,Dependoviruses,Virus, Adeno Associated,Viruses, Adeno Associated

Related Publications

R W Herzog, and E Y Yang, and L B Couto, and J N Hagstrom, and D Elwell, and P A Fields, and M Burton, and D A Bellinger, and M S Read, and K M Brinkhous, and G M Podsakoff, and T C Nichols, and G J Kurtzman, and K A High
Gene therapy for hemophilia B mediated by recombinant adeno-associated viral vector with hFIXR338A, a high catalytic activity mutation of human coagulation factor IX.
December 2001, Science in China. Series C, Life sciences,
R W Herzog, and E Y Yang, and L B Couto, and J N Hagstrom, and D Elwell, and P A Fields, and M Burton, and D A Bellinger, and M S Read, and K M Brinkhous, and G M Podsakoff, and T C Nichols, and G J Kurtzman, and K A High
Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy.
August 1999, Thrombosis and haemostasis,
R W Herzog, and E Y Yang, and L B Couto, and J N Hagstrom, and D Elwell, and P A Fields, and M Burton, and D A Bellinger, and M S Read, and K M Brinkhous, and G M Podsakoff, and T C Nichols, and G J Kurtzman, and K A High
Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
January 2004, Blood,
R W Herzog, and E Y Yang, and L B Couto, and J N Hagstrom, and D Elwell, and P A Fields, and M Burton, and D A Bellinger, and M S Read, and K M Brinkhous, and G M Podsakoff, and T C Nichols, and G J Kurtzman, and K A High
Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery.
January 2014, Molecular therapy. Methods & clinical development,
R W Herzog, and E Y Yang, and L B Couto, and J N Hagstrom, and D Elwell, and P A Fields, and M Burton, and D A Bellinger, and M S Read, and K M Brinkhous, and G M Podsakoff, and T C Nichols, and G J Kurtzman, and K A High
Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.
September 2003, Blood,
R W Herzog, and E Y Yang, and L B Couto, and J N Hagstrom, and D Elwell, and P A Fields, and M Burton, and D A Bellinger, and M S Read, and K M Brinkhous, and G M Podsakoff, and T C Nichols, and G J Kurtzman, and K A High
Adeno-associated virus-mediated gene transfer for hemophilia B.
November 2002, International journal of hematology,
R W Herzog, and E Y Yang, and L B Couto, and J N Hagstrom, and D Elwell, and P A Fields, and M Burton, and D A Bellinger, and M S Read, and K M Brinkhous, and G M Podsakoff, and T C Nichols, and G J Kurtzman, and K A High
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
March 2018, Blood,
R W Herzog, and E Y Yang, and L B Couto, and J N Hagstrom, and D Elwell, and P A Fields, and M Burton, and D A Bellinger, and M S Read, and K M Brinkhous, and G M Podsakoff, and T C Nichols, and G J Kurtzman, and K A High
Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
February 2001, Proceedings of the National Academy of Sciences of the United States of America,
R W Herzog, and E Y Yang, and L B Couto, and J N Hagstrom, and D Elwell, and P A Fields, and M Burton, and D A Bellinger, and M S Read, and K M Brinkhous, and G M Podsakoff, and T C Nichols, and G J Kurtzman, and K A High
Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A.
December 2022, Blood,
R W Herzog, and E Y Yang, and L B Couto, and J N Hagstrom, and D Elwell, and P A Fields, and M Burton, and D A Bellinger, and M S Read, and K M Brinkhous, and G M Podsakoff, and T C Nichols, and G J Kurtzman, and K A High
Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
May 2017, Human gene therapy,
Copied contents to your clipboard!